查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995211

基因型鑒定市場：依檢體類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Genotyping Market by Sample Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因型鑒定市值將達到 1,543.8 億美元，到 2026 年將成長至 1,657.6 億美元，到 2032 年將達到 2,824.8 億美元，複合年成長率為 9.01%。

主要市場統計數據
基準年 2025 1543.8億美元
預計年份：2026年 1657.6億美元
預測年份 2032 2824.8億美元
複合年成長率 (%) 9.01%

簡要概述基因型鑒定的進步、市場動態以及影響組織如何利用基因組數據產生可操作結果的策略挑戰。

基因型鑒定如今已成為生命科學、農業和臨床實踐等各個領域的基礎性能力，這得益於技術的成熟和不斷擴大的應用需求。隨著精準生物學從發現走向實用化，相關人員需要一個清晰的框架，來理解核心技術、最終用戶需求和樣本多樣性如何相互作用，從而創造機會並帶來挑戰。本文將當前趨勢置於這一更廣泛的背景下進行概述，重點關注檢測可重複性、樣本來源、工作流程整合和法規遵從性等實際問題。

新的技術突破、監管促進因素和經營模式轉型正在重新定義基因型鑒定的實踐和商業性部署。

基因型鑒定領域正經歷一系列變革，這些變革正在重塑調查、診斷和應用育種計畫的運作方式。在技​​術層面，定序化學的不斷改進以及數位PCR和先進微陣列技術的整合，提高了靈敏度，縮短了周轉時間，並增強了實驗設計的靈活性。生物資訊流程的改進進一步放大了這些進步，減少了分析瓶頸，並提高了不同樣本類型中變異檢測的可靠性。

對 2025 年美國推出的關稅措施對基因型鑒定生態系統的供應鏈、籌資策略和創新的影響進行全面評估。

美國2025年實施的關稅措施對基因型鑒定生態系統產生了複雜的影響，波及供應鏈、零件採購和籌資策略。近期營運方面的影響包括進口設備和試劑的接收成本增加，促使一些採購商重新審視其供應商組合併探索替代籌資策略。因此，採購團隊更重視供應商的韌性、本地庫存緩衝以及合約保障措施，以降低關稅導致的價格波動風險。

詳細的細分洞察揭示了技術、應用、最終用戶和樣本類型的趨勢，這些趨勢影響著產品的採用和創新需求。

詳細的細分框架闡明了基因型鑒定整體情況價值和技術差異的集中方向。在技​​術層面，微陣列、PCR 和定序平台之間的差異導致了截然不同的應用情境和投資模式。微陣列技術，包括比較基因組雜合反應和 SNP 晶片，在目標明確、注重成本效益的基因型鑒定中仍發揮重要作用，並被廣泛應用於大規模變異篩檢。 PCR 方法分為數位 PCR 和即時PCR兩種形式，二者優勢互補。數位 PCR 能夠對低等位基因頻率 (LAF) 進行超靈敏定量，而即時PCR則為常規檢測提供了高通量且經濟高效的工作流程。定序包括傳統的 Sanger 定序和次世代定序，其中次世代定序可進一步細分為EXOME、標靶定序和全基因組定序，其差異在於基因組分析的範圍和下游分析的複雜性。

美洲、歐洲、中東和非洲以及亞太地區的區域戰略展望：重點關注競爭優勢和能力差距

區域趨勢對基因型鑒定領域的策略和營運有顯著影響，每個區域都擁有其獨特的優勢、限制和商業管道。在美洲，強大的研究基礎設施和緊密的臨床及商業檢查室網路正在推動技術的快速應用和蓬勃發展的供應商生態系統，而政策變化和採購慣例則可能加速或阻礙引進週期。同時，歐洲、中東和非洲地區的環境則呈現出異質性，有些地區擁有健全的法規結構，而有些地區則存在能力差異，這既為集中式診斷服務創造了機遇，也為不同市場間的公平獲取帶來了挑戰。該地區的相關人員經常強調合規性、資料保護和跨境合作是關鍵的策略考量。

競爭情報和企業定位分析，揭示領先基因型鑒定公司的策略重點、合作趨勢和產能投資。

基因型鑒定領域的企業行為體現了技術主導差異化和策略組合管理的整合。主要企業正集中資源開發高價值能力，例如從樣本到結果的整合工作流程、雲端分析以及儀器和共同檢驗的試劑組合。儀器供應商和軟體供應商之間的合作日益普遍，這不僅能夠更緊密地整合檢查室工作流程和分析，還能加快獲得可操作結果的速度。同時，一些公司正在尋求垂直整合，以管理關鍵耗材並保護利潤率免受供應鏈中斷的影響。

為產業領導者提供具有重大影響力的策略建議，以加速技術採用、確保價值鏈並在基因型鑒定市場中獲取價值。

產業領導者應優先採取一系列措施，以加強其策略定位和業務永續營運。首先，他們應透過在特定檢體類型和對客戶至關重要的應用場景下檢驗平台效能，使技術選擇與最終用戶的工作流程相符。這種配對可以減少下游返工，並加快部署速度。其次，他們應探索區域製造或經銷夥伴，以實現供應商關係多元化，並降低關稅風險和物流中斷的影響。強調合約保障和庫存策略有助於在控制成本的同時確保服務的連續性。

嚴謹的調查方法，詳細說明了基因型鑒定研究過程中的資料來源、專家參與、檢驗過程和倫理保障措施。

本執行摘要依據的研究採用了一種多方面的方法，旨在確保研究的嚴謹性、透明度和可重複性。主要資料收集包括對臨床檢查室、農業育種計畫和學術研究計畫​​的從業人員進行結構化訪談，並輔以與採購和監管專家的諮詢，以了解營運和政策方面的觀點。次要研究則整合了同行評審的文獻、監管指南、儀器和檢測方法文檔以及公開的企業資訊披露，從而對研究結果進行多方面的檢驗，並將技術進步置於具體的背景之中。

整合相關人員的洞見：不斷發展的基因型鑒定領域面臨的策略挑戰概述及實現韌性和成長的途徑

總而言之，基因型鑒定技術正從局限於專業檢查室的模式轉變為支持大規模診斷、農業和研究的去中心化應用。定序、微陣列和PCR等技術的進步正在拓展可行檢測的範圍，而不斷演變的經營模式和監管政策的調整則正在塑造其應用路徑。 2025年的關稅趨勢凸顯了供應鏈韌性的重要性，並加速了區域製造和供應商多元化的討論。細分市場分析表明，技術選擇必須根據應用需求、最終用戶能力以及不同樣本類型帶來的獨特挑戰進行客製化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章基因型鑒定市場樣本（按類型分類）

  • 動物
  • 人類
  • 微生物
  • 植物

第9章基因型鑒定市場：依技術分類

  • 微陣列
    • 比較基因雜合反應
    • SNP晶片
  • PCR
    • 數位的
    • 即時的
  • 定序
    • 新一代
      • EXOME
      • 目標類型
      • 全基因組
    • 桑格

第10章：基因型鑒定市場：依應用領域分類

  • 農業
    • 作物改良
    • 畜牧養殖
  • 臨床診斷
    • 癌症譜分析
    • 病原體檢測
  • 研究
    • 基因表現分析
    • 基因突變研究

第11章基因型鑒定市場：依最終用戶分類

  • 學術研究機構
  • 診斷檢測實驗室
  • 製藥和生物技術公司

第12章基因型鑒定市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章基因型鑒定市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章基因型鑒定市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因型鑒定市場

第16章：中國基因型鑒定市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Merck KGaA
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Revvity, Inc.
  • Standard BioTools Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-A77F2EE7AB77

The Genotyping Market was valued at USD 154.38 billion in 2025 and is projected to grow to USD 165.76 billion in 2026, with a CAGR of 9.01%, reaching USD 282.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 154.38 billion
Estimated Year [2026] USD 165.76 billion
Forecast Year [2032] USD 282.48 billion
CAGR (%) 9.01%

A concise orientation to genotyping advances, market dynamics, and strategic imperatives shaping how organizations harness genomic data for practical outcomes

Genotyping is now a foundational capability across life sciences, agriculture, and clinical practice, driven by converging technological maturity and expanding application demand. As precision biology moves from discovery to operational deployment, stakeholders require a clear framing of how core technologies, end-user requirements, and sample diversity interact to create both opportunity and complexity. This introduction situates current developments within that broader context, emphasizing pragmatic considerations such as assay reproducibility, sample provenance, workflow integration, and regulatory alignment.

Over the past decade, method-level innovations and process optimizations have lowered barriers to entry while simultaneously elevating expectations for data quality and interpretability. Consequently, organizations face trade-offs between throughput, per-sample cost, sensitivity, and bioinformatics burden. Readers should therefore anticipate that strategic decisions will hinge as much on systems design and vendor partnerships as on individual instrument capabilities. In addition, an evolving regulatory environment and shifting procurement practices are influencing timelines for clinical adoption and large-scale agricultural implementations. Taken together, these dynamics make a nuanced understanding of both technological characteristics and end-user workflows essential for effective planning and investment.

Emerging technological breakthroughs, regulatory catalysts, and business model transformations that are redefining genotyping practice and commercial pathways

The genotyping landscape is in the midst of several transformative shifts that are reshaping how research, diagnostics, and applied breeding programs operate. Technologically, the continued refinement of sequencing chemistries and the integration of digital PCR and advanced microarray modalities have improved sensitivity, reduced turnaround times, and enabled more flexible experimental designs. These advances are being amplified by improvements in bioinformatics pipelines, which reduce analytical bottlenecks and increase the reliability of variant calls across diverse sample types.

Concurrently, business models are evolving. Providers are moving from one-time instrument sales toward service-oriented offerings that bundle instruments, consumables, and cloud-enabled analytics. This transition is prompting new partnership structures between instrument manufacturers, reagent suppliers, and software firms. Regulatory maturation is also a critical inflection point; clearer guidance for diagnostic assays and harmonization efforts across jurisdictions are lowering entry barriers for clinically actionable genotyping tests, while creating more rigorous validation demands. Finally, ethical and data governance considerations are gaining prominence, requiring organizations to invest in consent frameworks and secure data architectures. In combination, these technological, commercial, and regulatory drivers are shifting competitive dynamics and creating pathways for accelerated adoption among well-prepared stakeholders.

Comprehensive assessment of how United States tariff measures introduced in 2025 influence supply chains, procurement strategies, and innovation in genotyping ecosystems

Tariff measures introduced by the United States in 2025 have produced a complex set of effects on genotyping ecosystems, influencing supply chains, component sourcing, and procurement strategies. Immediate operational impacts include elevated landed costs for imported instruments and reagents, prompting some buyers to re-evaluate supplier portfolios and to consider alternative sourcing strategies. In turn, procurement teams are placing greater emphasis on supplier resilience, local inventory buffers, and contractual protections to mitigate the risk of tariff-driven price volatility.

Beyond procurement, tariffs have incentivized manufacturers and distributors to reassess manufacturing footprints, with increasing consideration given to regionalization of production and nearshoring of critical reagent and instrument subassembly lines. This shift aims to reduce exposure to trade friction and to improve lead-time predictability. At the same time, some organizations are accelerating vertical integration to secure access to proprietary consumables and to preserve margins. Importantly, tariffs have also affected collaborative dynamics, encouraging closer partnerships between suppliers and large end users to underwrite inventory commitments or customized pricing arrangements. While these responses can enhance resilience, they also introduce strategic trade-offs around capital allocation and operational flexibility. Consequently, leadership teams must weigh short-term mitigation tactics against longer-term decisions about where to locate capacity and how to structure supplier relationships to support sustained innovation and reliable service delivery.

Granular segmentation insights illuminating technology, application, end-user and sample type dynamics that shape product adoption and innovation imperatives

A granular segmentation framework clarifies where value and technical differentiation are concentrated across the genotyping landscape. On the technology axis, distinctions among microarray, PCR, and sequencing platforms drive fundamentally different use cases and investment profiles. Microarray techniques, including comparative genomic hybridization and SNP arrays, remain relevant for targeted, cost-conscious genotyping and are commonly deployed for large-scale variant screening. PCR approaches, split between digital and real-time modalities, offer complementary strengths: digital PCR delivers ultra-sensitive quantitation for low-allele-fraction detection, while real-time PCR provides high-throughput, cost-effective workflows for routine assays. Sequencing encompasses both traditional Sanger approaches and next-generation sequencing, with next-generation methods further categorized into exome, targeted, and whole-genome applications that differ in breadth of genomic interrogation and downstream analytical complexity.

Turning to applications, agriculture, clinical diagnostics, and research exert distinct performance and regulatory demands. In agriculture, needs center on crop improvement and livestock breeding programs that require robust genotyping pipelines tolerant of diverse sample matrices and field-derived variability. Clinical diagnostics prioritize cancer profiling and pathogen detection, carrying stringent validation, traceability, and turnaround-time requirements. Research applications, such as gene expression analysis and genetic variation studies, often tolerate higher analytical complexity and iterative experimental designs. End-user segmentation differentiates academic and research institutes, diagnostic laboratories, and pharmaceutical and biotechnology companies, each with unique purchasing models, operational scales, and technical staff competencies. Lastly, sample-type segmentation-encompassing animal, human, microbial, and plant matrices-affects assay selection, extraction protocols, and quality-control thresholds. Synthesizing across these dimensions reveals that successful product and service strategies align technology capabilities to the nuanced demands of application domains, end-user workflows, and the idiosyncrasies of specific sample types.

Regional strategic perspectives across the Americas, Europe Middle East and Africa, and Asia-Pacific highlighting competitive strengths and capability gaps

Regional dynamics materially influence strategy and operations in the genotyping domain, with each geography presenting distinct strengths, constraints, and commercial channels. In the Americas, strong research infrastructure and a dense network of clinical and commercial laboratories drive rapid technology diffusion and a vibrant vendor ecosystem, while policy shifts and procurement practices can accelerate or constrain adoption cycles. Conversely, Europe, Middle East & Africa presents a heterogeneous environment in which robust regulatory frameworks in some jurisdictions coexist with capacity gaps elsewhere, creating both opportunities for centralized diagnostic services and challenges for equitable access across diverse markets. Stakeholders in this region often emphasize compliance, data protection, and cross-border collaboration as critical strategic considerations.

Meanwhile, the Asia-Pacific region exhibits rapid capacity expansion, driven by investments in sequencing infrastructure, government-backed genomics initiatives, and a growing base of local manufacturing and service providers. This regional momentum supports aggressive deployment in agricultural genomics and population-scale research, but it also raises competitive pressures and prompts incumbent international suppliers to adapt pricing and partnership models. Across all regions, differences in reimbursement environments, regulatory harmonization, and logistics performance shape procurement decisions and time-to-market timelines. Therefore, regional strategies should be calibrated to local regulatory regimes, talent availability, and supply-chain realities, while also factoring in opportunities for regional hubs and cross-border service models.

Competitive intelligence and corporate positioning analysis revealing strategic priorities, collaboration trends, and capability investments among leading genotyping firms

Corporate behavior in the genotyping space reflects a mix of technology-driven differentiation and strategic portfolio management. Leading companies are concentrating resources on high-value capabilities such as integrated sample-to-answer workflows, cloud-enabled analytics, and reagent portfolios that are co-validated with instruments. Partnerships between instrument vendors and software providers are increasingly common, enabling tighter integration of laboratory workflows and analytics while reducing time to actionable results. At the same time, several firms are pursuing vertical integration to control critical consumables and to protect margins against supply-chain disruption.

Competitive positioning also varies by focus area. Firms that emphasize assay robustness and regulatory-grade validation often target clinical diagnostic pathways, investing in quality systems and clinical partnerships. Companies that prioritize scalability and cost-efficiency direct efforts toward large-volume applications such as agricultural genotyping or population-scale research initiatives. Across the board, there is a discernible emphasis on service models that bundle instruments, reagents, and data interpretation to create predictable revenue streams and stronger customer lock-in. Strategic collaboration with contract research organizations, clinical networks, and agricultural extension services further extends reach and utility. Ultimately, successful companies balance short-term commercial execution with longer-term investment in platform extensibility and regulatory readiness.

High-impact strategic recommendations for industry leaders to accelerate technology adoption, secure supply chains, and capture value in genotyping landscapes

Industry leaders should pursue a set of prioritized actions to strengthen strategic positioning and operational resilience. First, align technology selection with end-user workflows by validating platform performance across the specific sample types and application contexts that matter to your customers. This alignment reduces downstream rework and accelerates adoption. Second, diversify supplier relationships and consider regional manufacturing or distribution partnerships to mitigate tariff exposure and logistic disruptions. Placing emphasis on contractual protections and inventory strategies can preserve service continuity while maintaining cost discipline.

Third, invest in integrated service models that combine instruments, consumables, and analytics into single offerings, thereby simplifying procurement and increasing perceived customer value. Fourth, accelerate investments in regulatory and quality capabilities to support clinical uptake, particularly for cancer profiling and pathogen detection assays that demand robust validation and traceability. Fifth, pursue partnerships with academic centers and agricultural research programs to pilot new applications and to co-develop validation studies that demonstrate real-world utility. Finally, embed data governance and ethical frameworks into product design and commercial agreements to address growing stakeholder expectations around consent, privacy, and data portability. Taken together, these recommendations will help organizations convert technological capabilities into sustainable competitive advantage while managing operational risk.

Rigorous research methodology detailing data sources, expert engagements, validation processes, and ethical safeguards applied throughout the genotyping study

The research underpinning this executive summary employed a multi-method approach designed to ensure rigor, transparency, and reproducibility. Primary data collection included structured interviews with practitioners across clinical laboratories, agricultural breeding operations, and academic research programs, augmented by consultations with procurement and regulatory specialists to capture operational and policy perspectives. Secondary research synthesized peer-reviewed literature, regulatory guidance, instrument and assay documentation, and publicly available corporate disclosures to triangulate findings and to contextualize technological trajectories.

Data validation techniques included cross-verification of interview insights with documented product specifications and third-party validation studies, as well as iterative review cycles with domain experts to resolve discrepancies. Ethical safeguards were applied throughout the research process, including anonymization of interview responses and adherence to data protection best practices. Limitations of the study were acknowledged, notably the evolving nature of regulatory landscapes and the variability of regional procurement practices, which can introduce heterogeneity in adoption patterns. Nonetheless, the methodological combination of expert input, document analysis, and validation cycles provides a robust foundation for the strategic conclusions and recommendations presented here.

Synthesis of implications for stakeholders, outlining strategic imperatives and pathways to resilience and growth within the evolving genotyping sector

In sum, genotyping is transitioning from a technology constrained to specialized laboratories into a distributed capability that supports diagnostics, agriculture, and research at scale. Technological advances in sequencing, microarray, and PCR modalities are expanding the range of feasible assays, while evolving commercial models and regulatory clarity are shaping adoption pathways. Tariff-induced dynamics in 2025 have underscored the importance of supply-chain resilience and have accelerated conversations around regional manufacturing and supplier diversification. Segmentation insights reveal that technology choice must be matched to application demands, end-user capabilities, and the specific challenges posed by different sample types.

For stakeholders, the imperative is clear: build adaptable strategies that align platform selection, procurement practices, and regulatory readiness with the practical realities of deployment. Organizations that invest in integrated offerings, robust validation frameworks, and partnerships that bridge technical expertise with domain-specific needs will be best positioned to convert capability into tangible outcomes. Looking ahead, sustained attention to data governance, interoperability, and workforce capability will be essential in translating genotyping innovations into reliable, ethical, and scalable solutions that meet both commercial and societal needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genotyping Market, by Sample Type

  • 8.1. Animal
  • 8.2. Human
  • 8.3. Microbial
  • 8.4. Plant

9. Genotyping Market, by Technology

  • 9.1. Microarray
    • 9.1.1. Comparative Genomic Hybridization
    • 9.1.2. Snp Array
  • 9.2. Pcr
    • 9.2.1. Digital
    • 9.2.2. Real Time
  • 9.3. Sequencing
    • 9.3.1. Next Generation
      • 9.3.1.1. Exome
      • 9.3.1.2. Targeted
      • 9.3.1.3. Whole Genome
    • 9.3.2. Sanger

10. Genotyping Market, by Application

  • 10.1. Agriculture
    • 10.1.1. Crop Improvement
    • 10.1.2. Livestock Breeding
  • 10.2. Clinical Diagnostics
    • 10.2.1. Cancer Profiling
    • 10.2.2. Pathogen Detection
  • 10.3. Research
    • 10.3.1. Gene Expression Analysis
    • 10.3.2. Genetic Variation Studies

11. Genotyping Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Pharmaceutical And Biotechnology Companies

12. Genotyping Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genotyping Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genotyping Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Genotyping Market

16. China Genotyping Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. BGI Genomics Co., Ltd.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Danaher Corporation
  • 17.9. Eurofins Scientific SE
  • 17.10. F. Hoffmann-La Roche Ltd
  • 17.11. Illumina, Inc.
  • 17.12. Merck KGaA
  • 17.13. Oxford Nanopore Technologies plc
  • 17.14. Pacific Biosciences of California, Inc.
  • 17.15. PerkinElmer, Inc.
  • 17.16. QIAGEN N.V.
  • 17.17. Revvity, Inc.
  • 17.18. Standard BioTools Inc.
  • 17.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOTYPING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENOTYPING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOTYPING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENOTYPING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOTYPING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENOTYPING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOTYPING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENOTYPING MARKET SIZE, BY ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENOTYPING MARKET SIZE, BY ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOTYPING MARKET SIZE, BY ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENOTYPING MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOTYPING MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENOTYPING MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOTYPING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENOTYPING MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOTYPING MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENOTYPING MARKET SIZE, BY PLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOTYPING MARKET SIZE, BY PLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENOTYPING MARKET SIZE, BY PLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENOTYPING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOTYPING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENOTYPING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOTYPING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOTYPING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENOTYPING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOTYPING MARKET SIZE, BY SNP ARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENOTYPING MARKET SIZE, BY SNP ARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOTYPING MARKET SIZE, BY SNP ARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENOTYPING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOTYPING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENOTYPING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOTYPING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOTYPING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENOTYPING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOTYPING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENOTYPING MARKET SIZE, BY REAL TIME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOTYPING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOTYPING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOTYPING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENOTYPING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENOTYPING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOTYPING MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENOTYPING MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENOTYPING MARKET SIZE, BY EXOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOTYPING MARKET SIZE, BY EXOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENOTYPING MARKET SIZE, BY EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOTYPING MARKET SIZE, BY TARGETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOTYPING MARKET SIZE, BY TARGETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOTYPING MARKET SIZE, BY TARGETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENOTYPING MARKET SIZE, BY WHOLE GENOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOTYPING MARKET SIZE, BY WHOLE GENOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOTYPING MARKET SIZE, BY WHOLE GENOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOTYPING MARKET SIZE, BY SANGER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENOTYPING MARKET SIZE, BY SANGER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOTYPING MARKET SIZE, BY SANGER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOTYPING MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENOTYPING MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOTYPING MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOTYPING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENOTYPING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOTYPING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENOTYPING MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOTYPING MARKET SIZE, BY LIVESTOCK BREEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENOTYPING MARKET SIZE, BY LIVESTOCK BREEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOTYPING MARKET SIZE, BY CANCER PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENOTYPING MARKET SIZE, BY CANCER PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOTYPING MARKET SIZE, BY CANCER PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENOTYPING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOTYPING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENOTYPING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOTYPING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENOTYPING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOTYPING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOTYPING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENOTYPING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOTYPING MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENOTYPING MARKET SIZE, BY GENETIC VARIATION STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOTYPING MARKET SIZE, BY GENETIC VARIATION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENOTYPING MARKET SIZE, BY GENETIC VARIATION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENOTYPING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOTYPING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENOTYPING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOTYPING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENOTYPING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOTYPING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENOTYPING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOTYPING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENOTYPING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOTYPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS GENOTYPING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL GENOTYPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GCC GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 212. GCC GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 213. GCC GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 214. GCC GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 216. GCC GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 218. GCC GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. G7 GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 248. G7 GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. G7 GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 250. G7 GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 254. G7 GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. NATO GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 260. NATO GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. NATO GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 262. NATO GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 264. NATO GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 266. NATO GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL GENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA GENOTYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA GENOTYPING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA GENOTYPING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA GENOTYPING MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA GENOTYPING MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA GENOTYPING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA GENOTYPING MARKET SIZE, BY NEXT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA GENOTYPING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA GENOTYPING MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA GENOTYPING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA GENOTYPING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA GENOTYPING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)